<div id="readability-page-1"><p>Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 7,437 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares in the company, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p><p>Christopher Heery also recently made the following trade(s): </p><ul><li>On Monday, January 12th, Christopher Heery sold 6,131 shares of Arcellx stock. The stock was sold at an average price of $64.15, for a total value of $393,303.65. </li><li>On Monday, November 17th, Christopher Heery sold 340 shares of Arcellx stock. The stock was sold at an average price of $90.00, for a total value of $30,600.00. </li></ul><h2>Arcellx Stock Performance</h2><p>ACLX stock traded up $1.88 during trading on Tuesday, hitting $66.75. The stock had a trading volume of 520,715 shares, compared to its average volume of 817,595. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -16.98 and a beta of 0.36. The company's 50 day moving average price is $73.26 and its two-hundred day moving average price is $74.89. Arcellx, Inc. has a 1-year low of $47.86 and a 1-year high of $94.07. </p><p>Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.03). The business had revenue of $4.95 million for the quarter, compared to analysts' expectations of $11.24 million. Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%. As a group, sell-side analysts forecast that  Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several analysts have commented on the company. Wolfe Research assumed coverage on Arcellx in a report on Tuesday, November 18th. They issued a &#34;peer perform&#34; rating for the company. Guggenheim  restated a &#34;buy&#34; rating on shares of Arcellx in a report on Monday, November 24th. Cantor Fitzgerald  reaffirmed a &#34;neutral&#34; rating and set a $88.00 price target on shares of Arcellx in a research note on Thursday, October 9th. UBS Group began coverage on shares of Arcellx in a report on Wednesday, January 7th. They issued a &#34;buy&#34; rating on the stock. Finally, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Arcellx in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $112.22.</p><p><b>View Our Latest Stock Analysis on Arcellx</b></p><h2>Hedge Funds Weigh In On Arcellx</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. MAI Capital Management acquired a new stake in shares of  Arcellx in the 3rd quarter worth about $26,000.  CWM LLC grew its position in  Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company's stock worth $28,000 after purchasing an additional 251 shares during the last quarter.  State of Wyoming acquired a new stake in shares of  Arcellx in the second quarter valued at approximately $28,000.  Ramirez Asset Management Inc. bought a new stake in shares of  Arcellx during the third quarter valued at approximately $41,000.  Finally, PNC Financial Services Group Inc. boosted its position in shares of  Arcellx by 183.4% during the second quarter. PNC Financial Services Group Inc. now owns 751 shares of the company's stock worth $49,000 after buying an additional 486 shares during the period. Institutional investors and hedge funds own  96.03% of the company's stock. </p><h2>About Arcellx</h2> (Get Free Report)<p>Arcellx, Inc <span>NASDAQ: ACLX<span></span></span> is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.  </p><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Arcellx</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>First Time Since 2007: All Warnings Active</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcellx Right Now?</h2><p>Before you consider Arcellx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p><p>While Arcellx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACLX

<p>Arcellx insider Christopher Heery sold 7,437 shares at $65.51, totaling $487,197.87, reducing his ownership by 20.06%. He now holds 29,631 shares valued at approximately $1.94 million. This sale follows previous transactions, including 6,131 shares sold at $64.15 and 340 shares at $90.00. Arcellx's stock is currently trading at $66.75, with a market cap of $3.86 billion. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $112.22. Institutional investors own 96.03% of the company.</p>

Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock